What Acetyl Hexapeptide-8 is
Acetyl hexapeptide-8 is a cosmetic peptide used in topical skin-care discussions around expression lines and surface appearance.
Acetyl Hexapeptide-8 is grouped under Longevity + Skin on PeptideFactCheck because it is one of the most visible peptide names in cosmetic skin care, even for people who are not deep in biotech discussions.
The useful starting point is to separate the molecule itself from the internet story around it. It is one of the most visible peptide names in cosmetic skin care, even for people who are not deep in biotech discussions.
Why people keep looking it up
It is one of the most visible peptide names in cosmetic skin care, even for people who are not deep in biotech discussions.
Acetyl hexapeptide-8 is a cosmetic peptide used in topical skin-care discussions around expression lines and surface appearance.
Acetyl Hexapeptide-8 tends to stay in the conversation because it touches a familiar public theme: cosmetic peptide, expression-line discussion, and topical skin. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Popular cosmetic peptide with modest evidence and a lot of marketing amplification.
Most of the evidence sits closer to cosmetic-product literature than rigorous medical-style clinical proof.
Mechanistic stories usually center on neurotransmitter-related or expression-line theory rather than deep therapeutic evidence.
Why this page carries the current tier: Popular cosmetic peptide with modest evidence and a lot of marketing amplification.
The current seed trail for Acetyl Hexapeptide-8 is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Topical cosmetic peptides should not be framed like clinically proven systemic therapies.
This sits in cosmetic-product territory rather than a clear FDA-approved peptide-drug framework.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Acetyl Hexapeptide-8. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Acetyl Hexapeptide-8 is CID 71587772. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 71587772
- Formula
- C35H62N14O11S
- Molecular weight
- 887.0
- InChIKey
- AJLNZWYOJAWBCR-OOPVGHQCSA-N
Matched synonyms include Acetyl hexapeptide-3, Acetyl Hexapeptide-8, Argireline NP, Hexapeptide 3, L4EL31FWIL, Acetyl hexapeptide 3, Acetyl-glu-glu-met-gln-arg-arg-amide, DTXSID201021291.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Acetyl Hexapeptide-8 returns 6 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Acetyl Hexapeptide-8 returns 36 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Stretch Marks cream
- Generic names
- SESAMUM INDICUM (SESAME) SEED EXTRACT,PRUNUS PERSICA (PEACH) RESIN EXTRACT,STERCULIA URENS GUM,TRIPEPTIDE-1,HEXAPEPTIDE-9,ACETYL TETRAPEPTIDE-9,PALMITOYL PENTAPEPTIDE-4,PALMITOYL TETRAPEPTIDE-7,ACETYL HEXAPEPTIDE-8.
- Routes
- TOPICAL
- Application numbers
- M016
Indications and usage. INDICATIONS & USAGE Stretch Marks cream,removes scars, repairs, and enhances skin elasticity. Apply all over the body, concentrating on the abdomen. Apply to skin every morning and evening.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.